BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 2180568)

  • 1. Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy.
    Chudecka-Głaz A; Strojna A; Michalczyk K; Wieder-Huszla S; Safranow K; Skwirczyńska E; Jurczak A
    Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity.
    Park KC; Dharmasivam M; Richardson DR
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of trypsin and protease-activated receptor-2 in ovarian cancer.
    Kim KK; Turner R; Khazan N; Kodza A; Jones A; Singh RK; Moore RG
    PLoS One; 2020; 15(5):e0232253. PubMed ID: 32365084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Report on Finding a New Peptide Aldehyde from Cyanobacterium
    Nowruzi B; Wahlsten M; Jokela J
    Iran J Biotechnol; 2019 Apr; 17(2):e1853. PubMed ID: 31457050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bad Tumors Made Worse: SPINK1.
    Mehner C; Radisky ES
    Front Cell Dev Biol; 2019; 7():10. PubMed ID: 30778387
    [No Abstract]   [Full Text] [Related]  

  • 6. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of modular dual enzyme-responsive peptides.
    Boehnke N; Maynard HD
    Biopolymers; 2017 Sep; 108(5):. PubMed ID: 28799649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.
    Mehner C; Oberg AL; Kalli KR; Nassar A; Hockla A; Pendlebury D; Cichon MA; Goergen KM; Maurer MJ; Goode EL; Keeney GL; Jatoi A; Sahin-Tóth M; Copland JA; Radisky DC; Radisky ES
    Oncotarget; 2015 Nov; 6(34):35737-54. PubMed ID: 26437224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue.
    Stenman M; Ainola M; Valmu L; Bjartell A; Ma G; Stenman UH; Sorsa T; Luukkainen R; Konttinen YT
    Am J Pathol; 2005 Oct; 167(4):1119-24. PubMed ID: 16192646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and characterization of trypsinogen produced in the human male genital tract.
    Paju A; Bjartell A; Zhang WM; Nordling S; Borgström A; Hansson J; Stenman UH
    Am J Pathol; 2000 Dec; 157(6):2011-21. PubMed ID: 11106574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.
    Fishman DA; Kearns A; Larsh S; Enghild JJ; Stack MS
    Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):765-9. PubMed ID: 10417342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients.
    Hedström J; Sainio V; Kemppainen E; Haapiainen R; Kivilaakso E; Schröder T; Leinonen J; Stenman UH
    BMJ; 1996 Aug; 313(7053):333-7. PubMed ID: 8760740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of one- and two-chain forms of trypsinogen 1 produced by a human gastric adenocarcinoma cell line.
    Koshikawa N; Yasumitsu H; Nagashima Y; Umeda M; Miyazaki K
    Biochem J; 1994 Oct; 303 ( Pt 1)(Pt 1):187-90. PubMed ID: 7945238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2.
    Koivunen E; Itkonen O; Halila H; Stenman UH
    Cancer Res; 1990 Apr; 50(8):2375-8. PubMed ID: 2180568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis.
    Itkonen O; Koivunen E; Hurme M; Alfthan H; Schröder T; Stenman UH
    J Lab Clin Med; 1990 Jun; 115(6):712-8. PubMed ID: 2366031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
    Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH
    Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human trypsinogens in the pancreas and in cancer.
    Itkonen O
    Scand J Clin Lab Invest; 2010 Apr; 70(2):136-43. PubMed ID: 20163205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
    Stenman UH
    Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.